CoChat

Characterization of Serous Retinopathy Associated with Cobimetinib: Integrated Safety Analysis of Four Studies

Open access

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Abstract

INTRODUCTION AND OBJECTIVE: Serous retinopathy can be associated with MEK inhibitors, including cobimetinib. We present results of an integrated safety analysis to further characterize ocular functional and structural changes due to serous retinopathy. METHODS: Four studies evaluating cobimetinib at the approved dose and schedule in combination with other oncology drugs were included. Study CO39721 incorporated standardized ophthalmologic assessments to fully characterize serous retinopathy events over time and was the primary study for analysis. Supporting information was provided by studies GO28141, WO29479, and GO30182. RESULTS: In total, 655 patients received one or more doses of cobimetinib and comprised the safety-evaluable population. Overall, 117 patients (17.9%) had one or more serous retinopathy events, 24 (3.7%) had two or more events, and four (0.6%) had three or more events. Grade 3 events occurred in < 2.5% of patients. In CO39721, the median time to onset was 15 days (range 7-111); median time to resolution of first occurrence was 26 days (range 6-591 + days). Twelve of 25 patients (48.0%) recovered without a dose modification and 4/25 (16.0%) were recovered/recovering following a dose modification. The most frequent presentation of serous retinopathy was focal subretinal fluid on optical coherence tomography (62.8% of cases); in some instances (25.7% of cases), subretinal fluid was multifocal. There was no loss of visual function or visual acuity at serous retinopathy onset or resolution. CONCLUSIONS: Results from this integrated safety analysis indicate that cobimetinib-associated serous retinopathy can be managed with or without a dose modification of cobimetinib at the discretion of the treating physician. No visual loss or permanent retinal damage was identified on comprehensive ophthalmologic assessments. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov identifiers: NCT03178851, NCT01689519, NCT02322814, and NCT02788279.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40264-022-01248-2

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 4

Metadata

Authors
Barteselli, G., Goodman, G. R., Patel, Y., Caro, I., Xue, C., & McCallum, S.
Affiliations
  • Roche (United States) (US)
  • Roche (United Kingdom) (GB)
  • Roche (Canada) (CA)
Corresponding author
McCallum, Samuel
Venue
Drug Safety
Published
2022-10-30
Volume
45
Issue
12
Pages
1491-1499
ISSN
  • 0114-5916 (ISSN-L)
  • 1179-1942
OpenAlex
W4307642528
Cited by
4
References
28
Citations by year
2026: 1 · 2024: 1 · 2023: 1 · 2022: 1
FWCI
0.67
Type
journal article
Language
en
Open access
Licence
Locations
  • Drug Safety (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
Funders
F. Hoffmann-La Roche Ltd
Topics
  • Health Sciences › Medicine › Ophthalmology › Drug-Induced Ocular Toxicity
  • Health Sciences › Medicine › Ophthalmology › Ocular Oncology and Treatments
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
Keywords
cobimetinib, MEK inhibitors, drug-induced ocular toxicity, subretinal fluid, dose adjustment, visual acuity, integrated safety analysis
MeSH terms
Azetidines, Humans, Piperidines, Retinal Diseases, Protein Kinase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Characterization of Serous Retinopathy Associated with Cobimetinib: Integrated Safety Analysis of Four Studies. https://app.cochat.ai/papers/10.1007/s40264-022-01248-2
The paper
Barteselli, G., Goodman, G. R., Patel, Y., Caro, I., Xue, C., & McCallum, S. (2022). Characterization of Serous Retinopathy Associated with Cobimetinib: Integrated Safety Analysis of Four Studies. Drug Safety. https://doi.org/10.1007/s40264-022-01248-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.